TrialHepatology communications2022

Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study.

Kathleen M Loomes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.